Effect of NPB Capsules Consisting of Allium sativum, Hibiscus sabdariffa, Alisma plantago-aquatica, and Gynostemma pentaphyllum on Lipid Metabolism Disorders

Dyslipidemia is a common metabolic disorder marked by elevated total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C), and/or reduced high-density lipoprotein cholesterol (HDL-C). It is a key contributor to atherosclerosis. This study evaluated the therapeutic effects of NPB capsules in a murine model of dyslipidemia. The murine model was used to assess NPB capsules’ ability to modulate lipid dysregulation by inhibiting cholesterol esterase (CE) and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase enzymes. In vitro assays showed that NPB capsules significantly inhibited cholesterol esterase (26.94%) and HMG-CoA reductase (41.98%). In vivo, NPB capsules reduced intestinal cholesterol absorption and hepatic lipogenesis, improving serum lipid profiles. These findings indicate NPB capsules’ potential as an herbal candidate for dyslipidemia management and support the utility of further clinical investigation.